Bibliographic Details
| Title: |
Clinical efficacy and safety of flumatinib versus dasatinib combined with multi-drug chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia |
| Authors: |
Qian Liu, Tie Rong Bian, Zhi Yuan Li, Hong Yun Xing |
| Source: |
Hematology, Transfusion and Cell Therapy, Vol 46, Iss , Pp S71-S78 (2024) |
| Publisher Information: |
Elsevier, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Diseases of the blood and blood-forming organs |
| Subject Terms: |
Philadelphia chromosome-positive Acute lymphoblastic leukemia, Flumatinib, Dasatinib, Efficacy, Adverse reactions, Diseases of the blood and blood-forming organs, RC633-647.5 |
| More Details: |
Introduction: Flumatinib, a highly selective ABL kinase inhibitor, exhibits stronger inhibition of intracellular BCR-ABL tyrosine kinase activity, compared to Imatinib. However, there is limited research comparing the real-world efficacy and safety of flumatinib and dasatinib in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Objective: Investigating the differences in therapeutic efficacy and safety between flumatinib and dasatinib in combination with multi-drug chemotherapy for the treatment of newly diagnosed Ph+ ALL. Method: In this study, we assessed 43 patients with newly diagnosed Ph+ ALL (20 in the flumatinib group, 23 in the dasatinib group). Results: There were no significant differences in gender, age, fusion gene type, initial blood routine, bone marrow blast cell ratio or chromosome karyotype between the two groups. Within 1 month, there were no significant differences in the complete response (CR), major molecular response (MMR) or minimal residual disease (MRD) negativity rate between the flumatinib and dasatinib groups. Similarly, within 3 months, there were no significant differences in CR or MMR rates between the two groups. However, the rates of complete molecular response (CMR) and MRD negativity within 3 months were significantly higher in the flumatinib group, compared to the dasatinib group (P < 0.05). Additionally, the flumatinib group exhibited fewer adverse reactions compared to the dasatinib group. Conclusion: These findings suggest that flumatinib is a safe and effective tyrosine kinase inhibitor (TKI) for achieving CMR and MRD negativity in patients with Ph+ ALL, as supported by this small series of patients. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2531-1379 |
| Relation: |
http://www.sciencedirect.com/science/article/pii/S2531137924000130; https://doaj.org/toc/2531-1379 |
| DOI: |
10.1016/j.htct.2023.12.005 |
| Access URL: |
https://doaj.org/article/511c18057fd14c84a5d79b94dd1ae01b |
| Accession Number: |
edsdoj.511c18057fd14c84a5d79b94dd1ae01b |
| Database: |
Directory of Open Access Journals |
